Zelapar Valeant Pharmaceuticals International - Treatment for Parkinson’s Disease
Zelapar contains the a monoamine oxidase-B (MAO-B) inhibitor selegiline formulated using patented Zydis fast-dissolving technology which allows the tablets to dissolve within seconds in the mouth delivering more active drug at a lower dose. Zelapar is indicated as a once-daily oral adjunct therapy for Parkinson’s disease patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy.Posted: June 2006
Related articles
- Valeant Pharmaceuticals Receives Approvable Letter from FDA Regarding Zelapar - October 4, 2005
- Valeant Pharmaceuticals Submits Complete Response to FDA Approvable Letter for Zelapar - January 5, 2005
Zelapar (selegiline hydrochloride) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
